Carlsmed: Transforming Spine Surgery with AI-Powered Personalized Implants—Promising Growth Amid High-Risk, High-Reward Dynamics
Overview
Carlsmed, Inc. is an innovation-driven, AI-enabled medtech company recently going public, focused on transforming spine surgery through personalized, 3D-printed implants that leverage advanced imaging and algorithm-driven planning. Addressing a $13.4 billion spine fusion market, Carlsmed positions itself as a first-mover in combining artificial intelligence and custom manufacturing to target improved surgical outcomes and reduced complication rates. While posting nearly 100% revenue growth in 2024, the company remains loss-making, scaling up operations while benefiting from strong investor and insider backing. Carlsmed’s long-term outlook is founded on its differentiated technology in a large underserved market, but operational risks and the typical volatility of early-stage growth companies remain significant.